AI Article Synopsis

  • RH5 is a crucial protein that helps malaria parasites invade red blood cells by directly interacting with the host receptor basigin, forming a complex with proteins CyRPA and RIPR, making them potential vaccine targets.
  • Antibodies against RH5, CyRPA, and RIPR can block parasite invasion, indicating that a vaccine including these proteins could effectively prevent malaria.
  • The research also details the structural aspects of RH5 binding to P113, a protein that anchors RH5 to the parasite’s surface, providing insights that could facilitate the development of malaria vaccines targeting these interactions.

Article Abstract

RH5 is a secreted parasite ligand that is essential for erythrocyte invasion through direct interaction with the host erythrocyte receptor basigin. RH5 forms a tripartite complex with two other secreted parasite proteins, CyRPA and RIPR, and is tethered to the surface of the parasite through membrane-anchored P113. Antibodies against RH5, CyRPA, and RIPR can inhibit parasite invasion, suggesting that vaccines containing these three components have the potential to prevent blood-stage malaria. To further explore the role of the P113-RH5 interaction, we selected monoclonal antibodies against P113 that were either inhibitory or noninhibitory for RH5 binding. Using a Fab fragment as a crystallization chaperone, we determined the crystal structure of the RH5 binding region of P113 and showed that it is composed of two domains with structural similarities to rhamnose-binding lectins. We identified the RH5 binding site on P113 by using a combination of hydrogen-deuterium exchange mass spectrometry and site-directed mutagenesis. We found that a monoclonal antibody to P113 that bound to this interface and inhibited the RH5-P113 interaction did not inhibit parasite blood-stage growth. These findings provide further structural information on the protein interactions of RH5 and will be helpful in guiding the development of blood-stage malaria vaccines that target RH5. Malaria is a deadly infectious disease primarily caused by the parasite It remains a major global health problem, and there is no highly effective vaccine. A parasite protein called RH5 is centrally involved in the invasion of host red blood cells, making it-and the other parasite proteins it interacts with-promising vaccine targets. We recently identified a protein called P113 that binds RH5, suggesting that it anchors RH5 to the parasite surface. In this paper, we use structural biology to locate and characterize the RH5 binding region on P113. These findings will be important to guide the development of new antimalarial vaccines to ultimately prevent this disease, which affects some of the poorest people on the planet.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482062PMC
http://dx.doi.org/10.1128/mBio.01566-20DOI Listing

Publication Analysis

Top Keywords

rh5 binding
20
rh5
13
parasite
9
p113
8
binding site
8
secreted parasite
8
parasite proteins
8
cyrpa ripr
8
inhibit parasite
8
blood-stage malaria
8

Similar Publications

Article Synopsis
  • * Evidence shows that the invasion process involves manipulating RBC calcium signaling, particularly through the interaction between RH5 and basigin, which leads to increased cAMP and calcium influx in RBCs.
  • * The research highlights a conserved signaling pathway in host RBCs critical for parasite invasion and suggests new targets for therapeutic interventions against merozoite invasion.
View Article and Find Full Text PDF
Article Synopsis
  • PfRh5 has shown promise as a malaria vaccine candidate due to its key role in merozoite invasion and overall stability, with recent trials indicating its safety and effectiveness.
  • A study was conducted in Tanzanian regions known for high malaria transmission to assess genetic variation and immune responses to PfRh5 in asymptomatic carriers, revealing some new mutations but overall genetic conservation.
  • Results indicated variable immune response sensitivity tied to age, with the findings highlighting the importance of ongoing monitoring of vaccine efficacy and antigenic variation to improve malaria vaccine development.
View Article and Find Full Text PDF

RH5 antigenic landscape shapes vaccine and antibody development.

Trends Pharmacol Sci

December 2024

Host-Pathogen Interactions and Structural Vaccinology Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address:

The essential interaction between Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) and basigin makes RH5 a prime target for broadly neutralizing antibodies. A recent study by Barrett et al. mapped the RH5 antigenic landscape from RH5.

View Article and Find Full Text PDF

Genetic diversity in the Plasmodium falciparum next-generation blood stage vaccine candidate antigen PfCyRPA in Senegal.

medRxiv

October 2024

G4 Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.

Article Synopsis
  • * A study conducted in Senegal analyzed the genetic diversity of PfCyRPA in 95 malaria isolates, finding a mostly common wild type allele, with 15 identified single nucleotide polymorphisms (SNPs), mostly appearing as unique changes.
  • * Structure-based modeling showed that while most SNPs have minor effects on PfCyRPA antibodies, some may significantly affect its structure or interaction with the viral protein PfRH5, providing insights for future malaria vaccine design.
View Article and Find Full Text PDF

Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates.

NPJ Vaccines

October 2024

G4 - Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.

Vaccines to the Plasmodium falciparum reticulocyte binding-like protein homologue 5 (PfRH5) target the blood-stage of the parasite life cycle. PfRH5 has the potential to trigger the production of strain-transcendent antibodies and has proven its efficacy both in pre-clinical and early clinical studies. Vaccine-induced monoclonal antibodies (mAbs) to PfRH5 showed promising outcomes against cultured P.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!